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RANK brings Aire into the thymus
A group of epithelial cells in the 
thymus guard against autoimmunity 
by presenting self-antigens to de-
veloping T cells—those T cells that 
take the bait are then killed. On 
page 1267, Rossi et al. identify the 
signaling pathway that creates this 
epithelial barrier and the cells that 
activate this pathway.
Self-reactive T cells are elimi-
nated when they latch on to self-
antigens presented by a small subset 
of medullary thymic epithelial cells 
(mTECs). The self-antigens are 
derived from tissue-restricted proteins whose genes are expressed in the 
specialized mTECs under the supervision of the transcription factor Aire. 
Humans and mice that lack Aire develop multiorgan autoimmunity, but 
the mechanism that turns on Aire in the mTECs was not known.
Rossi et al. now show that Aire is activated in the mTECs through 
signaling via the TNF family receptor RANK, which is found on mTECs. 
Mice that lacked RANK failed to develop Aire-expressing mTECs and 
consequently suffered from autoimmunity. The ligand for RANK, 
RANKL, was provided by a haemopoietic cell population—the lymphoid 
tissue inducer (LTi) cells. These cells were previously known to reside in 
secondary lymphoid tissue. The team now finds that the LTi cells are 
also present in the thymus.
Not all mTECs express Aire, but whether this exclusivity is due to 
selective expression of RANK is unclear. The team is now investigating 
how LTi cell–mediated RANK signaling gets targeted to just a small 
thymic population. 
cAMP crosses junctions
Regulatory T (T reg) cells that cozy up to other 
T cells send inhibitory molecules through cell–cell 
gap junctions, according to a new study by 
Bopp et al. (page 1303).
Some thymus-born natural T reg cells need 
little more than direct contact with their T cell 
victims to suppress their immune functions. But the 
mechanism or molecule that controls this contact-
dependent inhibition has not yet been found.
One known potent immune suppressor is 
the intracellular second messenger cyclic 
adenosine monophophate (cAMP), which 
blocks T cell proliferation. cAMP levels are low 
in resting T cells and only marginally increase 
after activation. T reg cells, however, have 
constantly high levels of cAMP.
The team now shows that T reg cells use 
their abundant cAMP to flood conventional 
T cells and thereby shut them down. The cAMP 
transfer occurred through gap junctions, which 
formed upon contact between a T reg cell and 
an activated T cell. The subsequent increase in 
cAMP shut down T cell proliferation. cAMP 
transfer into activated T cells failed when gap 
junction formation was disrupted.
Together with Deaglio et al. (page 1257; 
and see “Regulatory cells get new ID” JEM 
204:1241), these studies confirm that T reg cells 
use cAMP and the adenosine-generating 
pathway to rein in immune activation. 
Vessel-widening by VEGF
A growth factor for blood vessels has also been touted as an inducer of lymph vessel growth. 
But Wirzenius et al. (page 1431) now find that, although the growth factor spurs the 
enlargement of existing lymph vessels, it does not induce the sprouting of new ones.
Lymph vessels are a follow-up act to blood vessels during embryogenesis. Vascular 
endothelial growth factor (VEGF) induces new blood vessel growth by binding to its 
receptor VEGFR-2 on vascular endothelial cells. VEGF-C and -D then kick off lymph 
vessel sprouting by binding to VEGFR-3 on lymphatic endothelial cells. But studies in 
mice that overexpress VEGF suggest that the two signaling pathways are not completely 
segregated. The abnormally large lymph vessels in these mice imply that VEGF somehow 
controls lymph vessel enlargement as well.
The team now finds that VEGFR-2 is also expressed on lymph vessels and induces their 
widening. But VEGF did not start lymph vessel growth anew: the missing lymph network of 
mouse embryos lacking VEGF-C and -D was not rescued by VEGF.
Lymphatic enlargement during inflammation helps immune cells accumulate at the site of 
injury or infection. But lymph vessels that don’t later slim down increase the risk of chronic 
inflammation. Lymph vessel expansion is also dangerous during tumor growth in lymph 
nodes, as enlarged vessels act as highways for metastasizing tumor cells. Current antitumor 
strategies that target VEGF prevent blood vessel growth and thus nutrient supply to tumors. 
This study suggests that anti-VEGF treatment may also prevent tumor metastasis. 
VEGF induces lymph vessel 
enlargement (top) but not the 
sprouting of new vessels (bottom).
Lymphoid thymic inducers (green) 
activate RANK to turn on Aire (red) 
in thymic cells (blue).